Combination of CHEK1 inhibitor and TOP1 inhibitor for treatment of colorectal cancer

Through the combination therapy of CHEK1 inhibitor and TOP1 inhibitor, especially the combination of camptothecin derivatives and CHEK1 inhibitors, the drug resistance and toxicity of colon cancer patients to monotherapy has been solved, and the intestinal cancer has been significantly improved. Treatment effect and patient survival rate.

CN118984707APending Publication Date: 2024-11-19GENOME RES LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033359.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-11
Filing Date
2023-02-10
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing single-drug targeted therapies have limited effectiveness in patients with bowel cancer, especially due to treatment difficulties and toxicity problems caused by drug resistance, and lack of effective treatment options.

Method used

Combination therapy of CHEK1 inhibitors and TOP1 inhibitors, especially the use of camptothecin derivatives (such as irinotecan) and CHEK1 inhibitors, to reduce dose and toxicity and improve the therapeutic effect on bowel cancer.

Benefits of technology

Larger tumor regression and increased survival were observed in intestinal cancer cells, especially for KRAS-TP53 double mutant colorectal cancer cells, providing better therapeutic response and lower toxicity .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005077294630000061
    Figure BDA0005077294630000061
  • Figure BDA0005077294630000062
    Figure BDA0005077294630000062
  • Figure BDA0005077294630000071
    Figure BDA0005077294630000071
Patent Text Reader

Abstract

The present invention relates to a combination therapy CHEK1 inhibitor and TOP1 inhibitor in a method for treating colorectal cancer in a patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to combination therapies for the treatment of cancer. Background Art

[0002] Despite advances in cancer treatment, it still has a significant impact on societies, families and individuals around the world. Cancer is one of the leading causes of death worldwide. According to the US National Cancer Institute, there were 18.1 million new cases of cancer and 9.5 million cancer-related deaths worldwide in 2018. By 2040, the number of new cancer cases is expected to rise to 29.5 million per year, and cancer-related deaths to 16.4 million. Bowel cancer is one of the most common types of cancer.

[0003] The use of single-agent targeted therapies for patients with molecularly defined tumors is improving cancer treatment. Despite this, many patients still lack effective treatments, and pre-existing or acquired drug resistance limits the clinical benefit of even our most advanced drugs. Combination therapies using a growing number of targeted anticancer drugs have the potential to overcome resistance, enhance responses to existing drugs, reduce the toxicity of dose-limiting single agents, and expand the therapeutic spectrum of patients. Summary of the invention

[0004] The present invention relates to the use of therapeutic combinations of active ingredients for treating bowel cancer in a patient, and in particular to the combination of a CHEK1 inhibitor and a TOP1 inhibitor, suitably a camptothecin. As described herein, the inventors have observed a synergistic effect of the combination of a CHEK1 inhibitor and a TOP1 inhibitor in cancer cell lines.

[0005] In a first aspect, the present invention can provide a combination of a CHEK1 inhibitor and a TOP1 inhibitor for use in a method for treating colorectal cancer in a patient. The TOP1 inhibitor irinotecan is of considerable significance for the treatment of colorectal cancer, but unfortunately is often associated with severe toxicity, especially neutropenia and diarrhea. The data generated by the inventors and described herein show that the combination of irinotecan and a CHEK1 inhibitor can promote the use of irinotecan in a dose-saving or split-dose method, opening up irinotecan-based therapy to patients with colorectal cancer for whom the established camptothecin-based regimen has been stopped or contraindicated. Therefore, the present invention can provide a camptothecin derivative (e.g., irinotecan) in a method for treating cancer in a patent, wherein the camptothecin derivative is administered together with the administration of a CHEK1 inhibitor in a dose-saving regimen. "Dose-saving" in this context should be understood to refer to the administration of a camptothecin derivative at a total dose lower than that used in a previously approved or tested treatment regimen.

[0006] The inventors further hypothesize that at currently used clinical doses, this combination may result in better responses, ie, greater tumor regression and / or increased survival.

[0007] In some cases, the present invention can provide a CHEK1 inhibitor for use in a method of treating colorectal cancer in a patient, and wherein the CHEK1 inhibitor is administered to the patient in combination with a TOP1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0008] In some cases, the present invention may provide a TOP1 inhibitor for use in a method of treating colorectal cancer in a patient, and wherein the TOP1 inhibitor is administered to the patient in combination with a CHEK1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0009] The inventors have identified a combination of a TOP1 inhibitor and a CHEK1 inhibitor as an effective combination in microsatellite stable (MSS) and / or KRAS-TP53 double mutant colon cancer cells that drives apoptosis and enhances response when compared to irinotecan alone.

[0010] Thus, in some embodiments, the colorectal cancer is a KRAS-TP53 double mutant colorectal cancer.A cancer may be, but need not be, microsatellite stable (ie, a cancer may be microsatellite unstable).

[0011] In some embodiments, the colorectal cancer is microsatellite stable.The cancer may be, but is not necessarily, a KRAS-TP53 double mutant colorectal cancer.

[0012] In some embodiments, the colorectal cancer is a KRAS-TP53 double mutant and microsatellite stable colorectal cancer.

[0013] Suitably, the TOP1 inhibitor is a camptothecin, for example selected from irinotecan, SN-38, topotecan and camptothecin. A preferred TOP1 inhibitor is irinotecan or its active metabolite. SN-38 is an active metabolite of irinotecan. That is, SN-38 is a preferred CHEK1 inhibitor. Another preferred CHEK1 inhibitor is camptothecin.

[0014] In some embodiments, the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prexasertib, MK-8776, CCT245737, CHIR-124, PF477736, VX-803, GDC-0575, ESP-01 and BEBT-260. In some embodiments, the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prexasertib and MK-8776. The preferred CHEK1 inhibitor is rabusertib.

[0015] It will be appreciated that the CHEK1 inhibitor and the TOP1 inhibitor may be administered together or separately, and may be administered simultaneously or at different times. For example, the compounds may be administered on different days as part of a treatment cycle or regimen. Suitably, but not necessarily, the CHEK1 inhibitor and the TOP1 inhibitor will be formulated separately. For example, each or any compound may be formulated for oral or parenteral administration.

[0016] The claimed combination therapies may be used both curatively and palliatively. They may result in better patient outcomes and / or experiences compared to other treatment options, and additionally or alternatively, they may expand the treatment options available to patients.

[0017] Suitably, the patient may be a human patient.

[0018] The present invention also relates to a method of treating colorectal cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of a CHEK1 inhibitor in combination with an effective amount of a TOP1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0019] The present invention also relates to a method of treating colorectal cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of a CHEK1 inhibitor in combination with an effective amount of a TOP1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0020] The present invention also relates to a method of treating colorectal cancer in a patient in need thereof, wherein the method comprises the step of administering to the patient an effective amount of a TOP1 inhibitor in combination with an effective amount of a CHEK1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0021] The present invention also relates to the use of a combination of a CHEK1 inhibitor and a TOP1 inhibitor in the preparation of a medicament for treating colorectal cancer in a patient, wherein the TOP1 inhibitor is a camptothecin derivative.

[0022] The present invention also relates to the use of a CHEK1 inhibitor in the preparation of a medicament for treating colorectal cancer in a patient in combination with a TOP1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0023] The present invention also relates to the use of a TOP1 inhibitor in the preparation of a medicament for treating colorectal cancer in a patient in combination with a CHEK1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

[0024] The present invention includes any combination of the described aspects and preferred features unless such a combination is expressly impermissible or explicitly avoided. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings, in which:

[0026] Figure 1 The synergistic effect and activity of the combination of camptothecin and AZD7762 in (A) colon cancer cells and (B) different colon cancer populations are shown. See Example 1 for more details.

[0027] Figure 2 The synergy and activity of the reference combination AZD7762 and 5-FU in colon cancer cells are shown. (A) MSI and MSS populations are compared. (B) The impact of TP53 mutations in KRAS mutant populations is focused on. See Example 2 for more details.

[0028] Figure 3 The ΔE of CHEK inhibitors in combination with camptothecin is shown max and ΔIC 50 See Example 3 for more details.

[0029] Figure 4 siRNA and Western blot results for combinations of CHEK inhibitors and camptothecin are shown: (A) Combined siRNA against CHEK1, CHEK2, or PLK1 (positive cell death control) + / - SN-38 (TOP1). Readout: Viability (CTG); (B) Western blot of (A) confirming knockdown of CHEK1 and CHEK2; (C) Individual siRNA against CHEK1 (positive cell death control) + / - SN-38 (TOP1). Readout: Viability (CTG); (D) Western blot of (C) confirming knockdown of CHEK1. See Example 3 for more details.

[0030] Figure 5 Colony formation is shown for the claimed combinations and for the compounds used alone. See Example 4 for more details.

[0031] Figure 6A snapshot of cell death signals recorded at 72 hours for the combination of rabusertib and TOP1i is shown. See Example 5 for more details.

[0032] Figure 7 PARP cleavage and cell death of the combination of rabusertib and TOP1i in SW837 and SNU-81 cells are shown. See Example 6 for more details.

[0033] Figure 8 (A) shows the change in tumor volume over time for irinotecan and rabusertib compared to the individual agents; (B) shows the change in tumor volume at the end point; (C) shows the survival of SNU-81 transplanted mice after the end of treatment. For more details, see Example 7.

[0034] Fig. 9 The effects of CHEK1i and TOPi on DNA double-strand breaks, apoptosis and proliferation in tumors are shown. See Example 8 for more details.

[0035] Fig.10 The IC of siCHEK1 against SN-38 is shown 50 See Example 9 for more details.

[0036] Fig.11 The sensitivity of colorectal cancer cell lines to a combination of CHEK1 and topoisomerase inhibitors is shown. As shown in each dot plot, colorectal cell lines were treated with topoisomerase inhibitor SN-38 plus CHEK1 inhibitor. Synergy measures (Bliss window and HSA window) were generated as described in Example 10. Each point is a single replicate, with 5-8 replicates for each cell line. DETAILED DESCRIPTION

[0037] Various aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference.

[0038] CHEK1 inhibitors

[0039] Checkpoint kinase 1 is often referred to as CHEK1 in the literature. Checkpoint kinases (CHEKs) are involved in the DNA damage response in many cancer cells, and CHEK1 inhibition is associated with DNA replication arrest, replication fork collapse, and accumulation of DNA damage.

[0040] The term CHEK1 inhibitor (also referred to as CHEK1i) refers to an inhibitor of CHEK1 that has a half-maximal inhibitory concentration (IC) of <15 nM (e.g., <10 nM) in a cell-free assay. 50) compounds. In some embodiments, the CHEK1 inhibitor has a half-maximal inhibitory concentration (IC) of <15 μM (such as <10 μM) in a cell-based assay. 50 ), to induce cell cycle arrest, or to inhibit phosphorylated-CHEK1 levels, or to induce DNA damage in cells. For example, based on an in vitro biochemical assay using recombinant CHEK1 kinase, rabusertib has an in vitro IC of 7 nM 50 (van Ark-Otte et al., Br J Cancer, 1998 Jun;77(12):2171-2176).

[0041] The inventors have observed that the combination response is CHEK1 specific. The compounds may also inhibit CHEK2, in which case they may be referred to as CHEK1 / 2i. Preferably, the combination comprises a CHEK1 specific inhibitor.

[0042] CHEK1 inhibitors include rabusertib, SAR-020106, AZD7762, prasetin, MK-8776, CCT245737, CHIR-124, PF-477736, VX-803, GDC-0575, ESP-01, and BEBT-260. In some embodiments, CHEK1 inhibitors include rabusertib, SAR-020106, AZD7762, prasetin, and MK-8776.

[0043] A preferred CHEK1i is rabusertib.

[0044] rabusertib

[0045] Rabusertib is also known as LY2603618 and IC-83. It is a highly selective CHEK1i with an IC of 50 is 7nM and has the following structure:

[0046]

[0047] In IUPAC nomenclature, it can be referred to as 1-[5-bromo-4-methyl-2-[[(2S)-morpholino-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea. It is commercially available.

[0048] SAR-020106

[0049] SAR-020106 is an ATP-competitive, potent and selective CHEK1 inhibitor with an IC of 50It has a concentration of 13.3 nM and good cell activity. It has the following structure:

[0050]

[0051] In IUPAC nomenclature, it can be referred to as 5-(8-chloroisoquinolin-3-ylamino)-3-((R)-1-(dimethylamino)propan-2-yloxy)pyrazine-2-carbonitrile. It is commercially available.

[0052] AZD7762

[0053] AZD7762 is a CHEK1 / 2 inhibitor. Its IC against CHEK1 in a cell-free assay is 50 is 5 nM and has the following structure:

[0054]

[0055] In IUPAC nomenclature, it may be referred to as (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide. It is commercially available.

[0056] Precetidine

[0057] Prilosec is also known as LY2606368 and ACR 368. It is a CHEK1 / 2 inhibitor with an IC of 1. 50 It has the following structure:

[0058]

[0059] In IUPAC nomenclature, it may be referred to as 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile. It is commercially available.

[0060] MK-8776

[0061] MK-8776 is also known as SCH 900776 and is a selective CHEK1 inhibitor with an IC of 50 It has a selectivity of 500-fold against CHEK2. It has the following structure:

[0062]

[0063] In IUPAC nomenclature, it may be referred to as 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine. It is commercially available.

[0064] CCT245737

[0065] CCT245737 is also known as SRA737 or PNT-737 and is an orally active CHEK1 inhibitor with IC 50 is 1.4 nM. It exhibits >1,000-fold selectivity against CHEK2. It has the following structure:

[0066]

[0067] In IUPAC nomenclature, it may be referred to as 5-methyl-N2-(5-methylpyrazin-2-yl)-N4-[[(2R)-morpholino-2-yl]methyl]pyridine-2,4-diamine. It is commercially available.

[0068] CHIR-124

[0069] CHIR-124 is a potent CHEK1 inhibitor with an IC of 50 is 0.3 nM. It shows 2,000-fold selectivity against CHEK2. It has the following structure:

[0070]

[0071] In IUPAC nomenclature, it can be referred to as 3-(1H-benzimidazol-2-yl)-6-chloro-4-[[(3S)-quinuclidin-3-yl]amino]-1H-quinolin-2-one. It is commercially available.

[0072] PF-477736

[0073] PF-477736 is also known as PF-736 or PF-00477736. It is a selective, potent and ATP-competitive CHEK1 inhibitor. In a cell-free assay, its Ki (dissociation constant) is 0.49 nM and its IC 50 The selectivity of CHEK1 is about 100 times that of CHEK2. It has the following structure:

[0074]

[0075] In IUPAC nomenclature, it can be referred to as (2R)-2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.0 4,13 ]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide. It is commercially available.

[0076] VX-803

[0077] VX-803 is also known as M4344. It is an ATP-competitive, orally active and selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with a Ki <150 pM. It is believed to inhibit ATR-driven phosphorylation of phospho-CHEK1 (P-CHEK1) with an IC of 1.1 in a cell-free assay. 50 It has the following structure:

[0078]

[0079] In IUPAC nomenclature, it may be referred to as 2-amino-6-fluoro-N-[5-fluoro-4-[4-[4-(oxetan-3-yl)piperazine-1-carbonyl]-1-piperidinyl]-3-pyridinyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide. It is commercially available.

[0080] GDC-0575

[0081] GDC-0575 is also known as ARRY-575 or RG7741. It is a potent and selective CHEK1 inhibitor with an IC 50 It has the following structure:

[0082]

[0083] In IUPAC nomenclature, it may be referred to as N-[4-[(3R)-3-amino-1-piperidinyl]-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide. It is commercially available.

[0084] ESP-01

[0085] ESP-01 (Esperas Pharma Inc) is also known as LY 2880070. It is a selective CHEK1 inhibitor and is being developed for the treatment of solid tumors, including metastatic colorectal cancer, epithelial ovarian cancer, endometrial cancer, soft tissue sarcoma, gastrointestinal stromal tumors (GIST), pancreatic cancer, and triple-negative breast cancer (TNBC). It is administered by oral route and is undergoing various clinical trials.

[0086] BEBT-260

[0087] BEBT-260 (Guangzhou BeBetter Medicine Technology Co Ltd) is a CHEK1 inhibitor. Related patents include EP3411036.

[0088] TOP1 inhibitors

[0089] DNA topoisomerase I is often referred to in the literature as TOP1. It controls and alters the topological state of DNA during transcription and is an attractive target in oncology.

[0090] TOP1 inhibitors previously used for clinical treatment include irinotecan and camptothecin. These are members of the compound class based on camptothecin, collectively referred to as camptothecins or camptothecin derivatives. That is, camptothecin derivatives refer to camptothecin itself or its derivatives based on the core camptothecin motif. Camptothecin derivatives include irinotecan, topotecan, belotecan, lurtotecan, exatecan, gimatecan and sinotecan. Alkylated, alkoxylated and hydroxylated derivatives have been reported in the literature. Therefore, TOP1 inhibitors can be selected from irinotecan, topotecan, belotecan, lurtotecan, exatecan, gimatecan and sinotecan, and alkylated, alkoxylated and hydroxylated derivatives thereof.

[0091] The inventors have observed that the combination reaction may be TOP1 specific. The compounds may also inhibit TOP2, in which case they may be referred to as TOP1 / 2i. Preferably, the combination comprises a TOP1 specific inhibitor.

[0092] Suitably, the TOP1 inhibitor used in the method of the present invention is a camptothecin derivative, for example selected from irinotecan, topotecan and camptothecin, or an active metabolite thereof, such as SN-38 (a metabolite of irinotecan). Preferably, the TOP1 inhibitor is camptothecin or SN-38. Even more preferably, the TOP1 inhibitor is SN-38.

[0093] Camptothecin

[0094] Camptothecin is also known as NSC-100880, CPT, DNA topoisomerase I inhibitor (Campathecin), and (S)-(+)-camptothecin. It is a specific inhibitor of TOP1 with an IC of 50 The concentration of 1 μM is 0.68 μM. Its structure is:

[0095]

[0096] In IUPAC nomenclature, it can be referred to as (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0 2,11 .0 4,9 .0 15,20 ] Heneicosane-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione. It is commercially available.

[0097] Irinotecan

[0098] Irinotecan is also known as CPT-11 and (+)-irinotecan. It is a topoisomerase I inhibitor in LoVo cells and HT-29 cells with an IC 50 15.8 μM and 5.17 μM, respectively (van Ark-Otte et al., Br J Cancer, 1998 June; 77(12): 2171-2176). Irinotecan is converted to SN-38 by carboxylesterase, which is the active metabolite. The structure of irinotecan is:

[0099]

[0100] In IUPAC nomenclature, it can be referred to as [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0 2,11 .0 4,9 .0 15,20 ]heneicosane-1(21),2,4(9),5,7,10,15(20)-hepten-7-yl]4-(1-piperidinyl)piperidine-1-carboxylate. It is commercially available, for example, as the hydrochloride salt.

[0101] Topotecan

[0102] Topotecan, also known as Hycamtin and Potactasol, is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases, particularly DNA topoisomerase I. Its structure is:

[0103]

[0104] In IUPAC nomenclature, it can be referred to as (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione or (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0 2,11 .0 4,9 .0 15 ,20 ] Heneicosine-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione. It is commercially available, for example, as the hydrochloride salt (which may be referred to as topotecan hydrochloride, Toporan, NSC609699, Nogitecan or SKFS104864A).

[0105] SN-38

[0106] SN-38 (also known as NK012) is also commercially available and has the structure:

[0107]

[0108] SN-38 is an active metabolite of irinotecan, and it inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 also induces autophagy. In IUPAC nomenclature, it can be referred to as (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0 2,11 .0 4,9 .0 15,20 ]Hexoneca-1(21),2,4(9),5,7,10,15(20)-heptene-14,18-dione.

[0109] Specific CHEK1 and TOP1 inhibitor combinations

[0110] In some cases, the combination of a CHEK1 inhibitor and a TOP1 inhibitor used in the treatment methods described herein can be a specific CHEK1 inhibitor and TOP1 inhibitor combination.

[0111] In some cases, the combination can be selected from: AZD7762 (CHEK1 inhibitor) and camptothecin (TOP1 inhibitor); MK-8776 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor); priseti (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor); rabusertib (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor); SAR-020106 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor); and CCT245737 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor).

[0112] In some cases, the combination used in the treatment methods described herein can be a combination of AZD7762 (CHEK1 inhibitor) and camptothecin (TOP1 inhibitor). In some cases, the combination used in the treatment methods described herein can be a combination of MK-8776 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor). In some cases, the combination used in the treatment methods described herein can be a combination of precipitin (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor). In some cases, the combination used in the treatment methods described herein can be a combination of rabusertib (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor). In some cases, the combination used in the treatment methods described herein can be a combination of SAR-020106 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor). In some cases, the combination used in the treatment methods described herein can be a combination of CCT245737 (CHEK1 inhibitor) and SN-38 (TOP1 inhibitor).

[0113] Pharmaceutically acceptable salts

[0114] As described herein, any compound may be provided as a pharmaceutically acceptable salt, hydrate or solvate. Suitable pharmaceutically acceptable salts are known in the art and are described, for example, in Berge et al., J Pharm Sci, 1977 66(1) p 1.

[0115] Application of active ingredients

[0116] The compound used in the method of the present invention can be administered by any suitable route, including oral and intravenous routes. It should be understood that oral administration may be preferred. The compound can be provided as a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients. The preparation for oral administration can be in the form of a tablet or a capsule comprising a powder or a liquid.

[0117] Administration is preferably a "therapeutically effective amount" or "effective amount" (used interchangeably), which is sufficient to show benefit to an individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the disease being treated. The prescription of treatment, such as dosage decisions, etc., is within the responsibility of general practitioners and other medical practitioners, and generally takes into account the condition to be treated, the condition of the individual patient, the site of administration, the method of administration, and other factors known to the physician. Examples of the above-mentioned techniques and protocols can be found in Remington's Pharmaceutical Sciences, 20th edition, 2000, pub. Lippincott, Williams & Wilkins.

[0118] Art-known dosing regimens for the active ingredients described herein may also be used in the present invention.

[0119] For example, in clinical trials, rabusertib was previously used at 150 mg / m 2 , 170mg / m 2 or 230 mg / m 2 Parenteral administration. See, e.g., Weiss et al. Invest New Drugs 2013 31(1):136-44 (PMID: 22492020), ClinicalTrials.gov Identifier: NCT01341457, Scagliotti et al. Invest New Drugs, 2016 Jun 27, 34(5):625-635 (PMID: 27350064).

[0120] For irinotecan as monotherapy, the recommended dose is 125-350 mg / m as an intravenous infusion. 2 Administration. The dosage depends on whether it is a once-weekly or twice- or thrice-weekly regimen. When used in combination with folinic acid (LV) and fluorouracil (5-FU), the dosage is 125-180 mg / m 2 , which depends on the regimen. See, e.g., https: / / www.pfizermedicalinformation.com / en-us / camptosar / dosage-admi n, https: / / www.medicines.org.uk / emc / product / 481 / smpc#gref, and https: / / reference.medscape.com / drug / camptosar-irinotecan-342252.

[0121] Therefore, the active ingredients described herein can be administered at a dosage of about 1 mg to about 1000 mg, such as about 5 mg to about 500 mg, such as about 10 mg to about 400 mg. In some embodiments, CHEK1 inhibitors (such as rabusertib) can be administered at a dosage of about 1 mg to about 1000 mg, such as about 50 mg to about 500 mg, such as about 100 mg to about 300 mg, such as about 170 mg to about 230 mg. In some embodiments, TOP1 inhibitors (such as camptothecin, such as irinotecan) can be administered at a dosage of about 1 mg to about 1000 mg, such as about 50 mg to about 500 mg, such as about 100 mg to about 400 mg, such as about 150 mg to about 350 mg.

[0122] As a dose-saving approach, CHEK1 inhibitors (such as rabusertib) can be administered at a full dose (such as 230 mg), and the concentration of TOP1 inhibitors (such as camptothecin, such as irinotecan) can be reduced to 1 / 10-1 / 2 of the full dose. For example, the full dose of irinotecan is 350 mg / m 2 . Half of the full dose of irinotecan can be taken at about 75 mg / m 2 To about 175mg / m 2 and 1 / 10 of the full dose of irinotecan can be at about 15 mg / m 2 Up to about 35 mg / m 2 within the range.

[0123] The active ingredients described herein can be administered simultaneously or sequentially. In some embodiments of the combination therapies described herein, CHEK1 and TOP1 inhibitors are administered sequentially. In some embodiments, TOP1 inhibitors (such as camptothecin, such as irinotecan) are administered first, followed by CHEK1 inhibitors (such as rabusertib).

[0124] Each of the CHEK1 and TOP1 inhibitors can be independently administered orally or parenterally. In some embodiments, the CHEK1 inhibitor (such as rabusertib) can be administered parenterally, such as intravenously. In some embodiments, the TOP1 inhibitor (such as camptothecin, such as irinotecan) can be administered parenterally, such as intravenously.

[0125] Active ingredients as described herein can be used at different times within a prescribed dosing cycle. Active ingredients as described herein can be used daily, such as once a day (QD), twice a day (BID), three times a day (TID) or four times a day (QID), or with a less frequent or intermittent schedule.

[0126] Suitably, the patient may be a human patient.

[0127] Combination with other chemotherapy agents

[0128] The compounds used in the methods of the present invention can be administered with one or more other active agents, such as other chemotherapeutic agents, for the treatment of colorectal cancer. For example, the combination therapy as described herein can be used in combination with other chemotherapeutic agents (such as platinum-based chemotherapy or gemcitabine or 5-FU or 5-FU used in combination with folinic acid). In such cases, the combination therapy (i.e., CHEK1 and TOP1 inhibitors) and the additional active agents can be administered together or separately, for example as ingredients in the same pharmaceutical composition or formulation, or as separate formulations.

[0129] Cancer Type

[0130] The present invention relates to methods for treating cancer in a patient, and in particular treating intestinal (colorectal) cancer. Thus, in some aspects, the present invention relates to treating colon cancer in a patient.

[0131] Suitably, the colorectal cancer is microsatellite stable (MSS). That is, the tumor is classified as MSS by genomic analysis and / or immunohistochemistry. Tumors that are not MSS are referred to as MSI-high (microsatellite instability-high). Genomic analysis to determine MSI / MSS status is described in Kawakami et al., Curr. Treat. Options Oncol., 2015 Jul; 16(7):30 (PMID: 26031544), and detection systems can be obtained, for example (OncoMate TM The MSIDxAnalysis System) is commercially available.

[0132] As can be seen from Example 1 and in particular Figure 1 As seen in a, the synergy and activity were significant in this patient population. That is, in colorectal cancer patients identified as having MSS tumor biomarkers. Estimates of the proportion of MSS colorectal tumors vary, but it is generally agreed that more than half of colorectal tumors are MSS.

[0133] In some embodiments, the colorectal cancer is a KRAS-TP53 double mutant colon cancer. In other words, the tumor is classified by genomic analysis as having both a KRAS mutation and a TP53 mutation.

[0134] The KRAS (Kirsten rat sarcoma virus) gene is an oncogene. KRAS mutations are thought to be associated with approximately 40% of colorectal cancers and can be determined by tests known in the art. Most methods involve using PCR to amplify the appropriate region of the KRAS gene, including exons 2 and 3, and then using different methods to distinguish wild-type from mutant sequences in key codons (such as 12 and 13). Detection methods include nucleic acid sequencing, allele-specific PCR methods, single-strand conformation polymorphism analysis, melting curve analysis, and probe hybridization. Tests used to detect KRAS mutations, such as The KRASMutation Test (Roche) and Therascreen KRAS RGQ PCR Kit (Qiagen) are both FDA-approved (https: / / www.fda.gov / medical-devices / in-vitro-diagnostics / list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools).

[0135] Tumor protein p53 (TP53) is a gene encoding a tumor suppressor protein that regulates the expression of genes involved in cell cycle arrest, apoptosis, senescence, DNA repair, and metabolic changes. TP53 mutations are associated with Li-Fraumeni syndrome and can be determined by tests known in the art. Methods for detecting and analyzing TP53 mutations include PCR assays that look for mutations present in exons 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 of TP53 (https: / / www.fda.gov / medical-devices / in-vitro-diagnostics / list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools).

[0136] like Figure 1 As shown in b, significantly higher degrees of efficacy and effectiveness were observed in the KRAS-TP53 double mutant population.

[0137] ***

[0138] The features disclosed in the foregoing description, in the appended claims or in the drawings, expressed in their specific form or, where appropriate, in the form of a means for performing the disclosed function or a method or process for obtaining the disclosed results, may be used alone or in any combination of such features to implement the invention in its various forms.

[0139] Although the present invention has been described in conjunction with the above exemplary embodiments, it will be apparent to those skilled in the art that many equivalent modifications and variations will be apparent after obtaining this disclosure. Therefore, the above exemplary embodiments of the present invention should be considered illustrative rather than restrictive. Various changes may be made to the embodiments without departing from the spirit and scope of the present invention.

[0140] To avoid any doubt, any theoretical explanations provided herein are for the purpose of enhancing the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.

[0141] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0142] Throughout this specification, including the appended claims, unless the context requires otherwise, the words "comprise" and "comprising" and variations such as "comprises", "comprising" and "including", will be understood to mean the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0143] It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by using the preposition "about", it is understood that the particular value constitutes another embodiment. The term "about" in relation to a numerical value is optional and, for example, means + / - 10%.

[0144] Example

[0145] Example 1

[0146] Combination synergy and activity rate in colon cancer

[0147] AZD7762 (CHEK1, CHEK2) was screened in combination with the TOP1 inhibitor camptothecin in colon (n=45) cancer cell lines. For efficient screening, the inventors used a 2×7 concentration matrix or "anchor" approach. The inventors screened discontinuous 1,000-fold (7-point) dose-response curves for each anchor compound and library compounds at two optimized concentrations. CellTiter-Glo was used to read the viability after 72 hours of drug treatment, and the drug responses of single agents and combination responses were fitted. Viability measurements of single agents and combinations were fitted to the cell line, and multiple parameters were derived, including: 1) anchor viability effect, 2) viability effect of the library and combination at the highest library concentration used (library E max and combination E max ), and 3) the estimated pool drug concentrations that produced a 50% reduction in activity (IC 50 The inventors compared the observed combination responses of cells with those predicted by the Bliss independence model based on the activity of the monotherapies and compared the observed combination responses with those predicted by the Bliss independence model based on the potency (ΔIC 50 ; i.e. increased sensitivity) or efficacy (ΔE max Drug combinations are classified by changes beyond Bliss in terms of β-category (i.e., decreased cell viability) (Bliss, Annals of Applied Biology, 1939, 26(3), 585-615). If at any anchor concentration, the combination IC 50 or E max The inventors classified the combination-cell line pair as synergistic when there was a 1 / 8 reduction or a 20% reduction in viability, respectively, relative to Bliss. Good synergy and activity levels were observed. See Table 1 - Synergy rates for colon cancer cell lines.

[0148] Table 1

[0149]

[0150] *The first compound listed is the anchor compound. This combination was tested in both orientations.

[0151] The synergy and activity rates were also divided into subgroups of MSS (n=30) and MSI (n=15), or KRAS mut (n=24) and KRAS wt (n=21) cell lines. More than 50% of MSS or KRAS mut colon cell lines showed synergy and activity. See Table 2.

[0152] Table 2

[0153]

[0154] The activity was compared in MSI (n=15) and MSS (n=30) cell lines ( Figure 1 a). KRAS mutant (n=24) and cell lines (n=8, TP53 wild-type; n=16, TP53 mutant) were studied ( Figure 1 b). Microsatellite stability (MSS) or TP53 mutations in the context of KRAS mutations sensitize colon cancer cells to treatment with AZD7762 and camptothecin. In both populations, the inventors observed efficacy (ΔIC 50 ) and efficacy (ΔE max ). Plotted are the mean combined responses. Box plots show medians and interquartile ranges. Two-sided Welch t-tests were performed (*=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001).

[0155] Example 2

[0156] Comparison with other combinations

[0157] AZD7762 (CHEK1, CHEK2) in combination with chemotherapeutic agents was screened in colon (n=45) cancer cell lines. CellTiter-Glo was used to read viability after 72 hours of drug treatment and drug responses were fitted for single agent and combination responses. Synergy was based on efficacy (ΔE max ) or potency (ΔIC 50 ) relative to the expected drug combination response [as calculated by Bliss; in ΔE max ≥20% activity or ΔIC 50 The activity is based on a significant change in the reduction in activity of the combination compared to the activity of the single agents (the combination showed a 20% greater reduction in activity than the two single agents). It can be seen that the synergy and activity of the claimed combination in colon cancer cell lines is higher than the combination of the CHEK1 inhibitor AZD7762 with other chemotherapeutic agents (Table 3).

[0158] Table 3

[0159]

[0160] The combination of AZD7762 and 5-FU was further investigated ( Figure 2 a, Figure 2 b). Microsatellite stability (MSS) or TP53 mutations in the context of KRAS mutations only slightly sensitized colon cancer cells to treatment with AZD7762+5-FU. In both populations, the inventors observed efficacy (ΔIC 50 ) and efficacy (ΔE max). Plotted are the mean combined responses. Box plots show medians and interquartile ranges. Two-sided Welch t-tests were performed (*=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001).

[0161] Example 3

[0162] CHEK1 specificity

[0163] To test CHEK specificity, the inventors seeded SW620, SW837, SNU-81, or LS-1034 cells in 96-well plates (770-2, 750 cells per well) and treated them with camptothecin (anchor, 0.025 μM) in combination with the following six CHEK inhibitors with different specificities (pool, all dosed at 1 μM top use concentration unless indicated): AZD7762 (CHEK1, CHEK2), prasetin (CHEK1, CHEK2), MK-8776 (CHEK1, CHEK2, CDK2), SAR-020106 (CHEK1), rabusertib (CHEK1), and CCT241533 (CHEK2; 2 μM). After 96 hours of drug treatment, the cells were plated with CellTiter- Viability was measured using CTGA 2.0 (CTG; Promega). Drug response curves were fitted and the combined response index ΔE was calculated by comparing the observed combined response with the expected (Bliss) combined response. max and ΔIC 50 . ΔE max and ΔIC 50 The higher the ΔIC, the stronger the combination response. SW620, SW837, SNU-81, and LS-1034 are all MSS and KRAS-TP53 double mutant colon cancer cell lines. The CHEK1 selective inhibitors SAR-020106 and rabusertib combined with camptothecin produced greater efficacy in the four cell lines (median ΔIC 50 : 8.5-10.5-fold change) and efficacy (median ΔE max :0.22-0.24), while the CHEK2 selective inhibitor CCT-241533 did not ( Figure 3 ).

[0164] siRNA experiments were also performed ( Figure 4 a and 4c). Figure 4 a shows A) Pooled siRNA against CHEK1, CHEK2 or PLK1 (positive cell death control) + / - SN-38 (TOP1). Readout: Viability (CTG). Figure 4 c shows individual siRNAs against CHEK1 (positive cell death control) + / - SN-38 (TOP1). Readout: Viability (CTG).

[0165] For siRNA experiments, SW837 and SNU-81 cells (8,000 and 16,000 cells per well, respectively) were reverse transfected with siRNAs of a non-targeting pool (siNT; Dharmacon, D-001810-10-05) as a negative control, a polo-like kinase 1 (PLK1) pool (Dharmacon, L-003290-00-0010) as a positive control, a CHEK1 pool (Dharmacon, L-003255-00-0005), or four individual CHEK1 siRNAs (LQ-003255-00-0005) and a CHEK2 pool (Dharmacon, L-003256-00-0005) using lipofectamine RNAiMax (Thermofisher). After 30 hours, 0.025 μM or a dose range of 0.001-9 μM SN-38 or DMSO was added, and viability was measured with CTG after 72 hours. Signals were normalized to siNT+DMSO control. Statistical significance between conditions was tested using Student's t-test, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. Figure 4 a and 4c confirmed that the effect of TOP1+CHEK combination was mainly mediated by inhibiting CHEK1.

[0166] Western blot analysis was also performed to confirm gene knockdown ( Figure 4 b and 4d). SW837 or SNU-81 cells were reverse transfected with siNT, siCHEK1 or siCHEK2 as described above. Cells were collected 72 hours after transfection and lysed in RIPA buffer (Sigma-Aldrich, R0278). Cell lysates were separated by SDS-PAGE, transferred to PVDF membranes and probed with anti-CHEK1 (Santa Cruz Biotechnology, sc-8408, 1:200; mouse), anti-CHEK2 (Cell Signaling Technologies, D9C6, 1:1000; rabbit) and anti-β-actin (Abcam, ab6276, 1:5000; mouse) as a loading control. Figure 4 b Knockdown of CHEK1 and CHEK2 was confirmed. Figure 4 d Confirmation of CHEK1 knockdown.

[0167] Example 4

[0168] Combinations compared with single agents

[0169] Cells (from cell lines LS-1034, SW837, and SNU-81) were seeded at 50,000 cells / well in 6-well plates. Drugs (0.1 nM SN-38, 0.5 μM rabusertib, 0.5 μM CCT241533) or DMSO were added on day 1 and refreshed by medium change on day 8. 14 days after the start of drug treatment, cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS (10 minutes at room temperature) and stained with Giemsa (10%; Sigma-Aldrich) for at least 30 minutes at room temperature.

[0170] If available from Figure 5 As can be seen, in the three separate cell lines tested, the combination of rabusertib (CHEK1) and TOP1i (SN-38) resulted in fewer colony formations than either the single agents or when TOP1i was combined with CCT241533 (a CHEK2 selective inhibitor).

[0171] The inventors note that quantification of the number of colonies formed is challenging due to their small size. This often depends on the cell line used.

[0172] Example 5

[0173] Rabusertib (CHEK1i) and TOP1i induce cell death beyond additive responses

[0174] Cells were seeded in 96-well plates (usually 5,000-16,000 cells per well). After 24 hours, drugs (0.125 μM staurosporine (positive control), 0.025 μM SN-38, 0.75 μM rabusertib, 0.75 μM CCT241533) or DMSO and a marker for cell death (CellTox TM Green; 1:1000; Promega) or caspase-3 / 7 activity ( Caspase-3 / 7Red; 1:1000; Essen Bioscience) real-time fluorescence reagent. Photos were recorded every 2 hours for 96 hours using Incucyte (Essen Bioscience). The recorded fluorescence signal was measured as the average intensity / cell area and normalized to time 0 hours. The average of 3-4 biological replicates.

[0175] Snapshots of cell death signals recorded over 72 hours have been converted into Figure 6Figure shown. GCU is the abbreviation of green calibration unit. The upper figure (three lines are observed-summed, summed and observed; wherein the observation-summed (GCU) scale is the key) shows the summed response (the sum of the single-agent responses of SN-38 and CHEKi; summed row) and the experimentally observed response (observation row), and Δ is the difference between the observed response and the summed response (observation-summed row). The middle figure (three lines of DMSO, SN-38 and CHEKi; wherein the CTOX signal (GCU) scale is the key) shows the effect of a single drug on cell death, wherein DMSO is used as a control in the absence of any drug. The lower figure (three lines of MSS, KRAS_mut and TP53_mut; wherein the colored features are the key) shows the mutation status of KRAS and TP53 in the cell line, as well as the microsatellite stability (MSS) status (wherein the cell line is identified along the bottom).

[0176] If available from Figure 6 As seen, in many colon cancer cell lines, especially those that were MSS or KRAS-TP53 double mutant, CHEK1i but not CHEK2i in combination with TOP1i resulted in increased cell death beyond an additive response.

[0177] Example 6

[0178] PARP cleavage determines cell death

[0179] SW837 (1 million) or SNU-81 (1.5 million) cells were seeded in 10 cm dishes and treated with drugs (0.025 nM SN-38, 1.5 μM rabusertib, 1.5 μM CCT241533, 2 μM MG-132 (positive control)) or DMSO the next day. After 72 hours, live and dead cells were collected and lysed in RIPA buffer (Sigma-Aldrich) supplemented with 1 mM DTT (Cayman Chemicals) and protease and phosphatase inhibitors (Roche). Cell lysates were separated by SDS-PAGE, transferred to PVDF membranes and probed with anti-PARP (Cell Signalling Technologies, 9542, 1:1,000; rabbit) and anti-β-tubulin (Sigma-Aldrich, T4026, 1:5,000; mouse) as a loading control. The results are shown in Figure 7 , which demonstrated that the combination resulted in increased cell death over that of the individual drugs.

[0180] Example 7

[0181] Effects of CHEK1i and TOPi on tumor volume change or survival

[0182] Place 4.5 x 10 6 LS-1034 cells, 5×10 6 SW837 cells or 2.5×10 6 SNU-81 cells were injected subcutaneously into the right flank of 6-week-old NOD / SCID mice. Once tumors reached approximately 300-400 mm 3 The mice were randomly assigned to treatment groups according to the mean volume of the retinal tissue culture medium: LS-1034: n = 6 mice for vehicle, n = 11 for irinotecan, n = 12 for rabusertib and irinotecan + rabusertib; SW837: n = 6 mice for vehicle and rabusertib, n = 8 for irinotecan, n = 4 for irinotecan + rabusertib. SNU-81: n = 5 mice for vehicle and irinotecan + rabusertib, n = 6 for rabusertib, n = 10 for irinotecan.

[0183] Rabusertib was administered orally at 200 mg / kg daily (vehicle: 16.66% CyDex Inc, in 25 mM phosphate buffer, pH 4); irinotecan was administered intraperitoneally at 25 mg / kg twice weekly (vehicle: saline). Tumor size was assessed once a week by caliper measurement and using the formula 4 / 3π·(d / 2) 2 The approximate volume of the mass was calculated as D / 2, where d is the short axis of the tumor and D is the long axis of the tumor. The tumor mass was evaluated when at least 4 mice in each treatment group reached the pre-specified endpoint (treatment for at least 3 weeks in trials designed to evaluate drug efficacy or a tumor mass greater than 1500 mm in each treatment group). 3 Development of tumors with an average volume greater than 750 mm at least 3 weeks after cessation of treatment in survival studies designed to assess tumor control by therapy 3 Results were considered interpretable when the volume of a single tumor was not measured (development of a single tumor). Operators were blinded during measurements. In vivo procedures and associated biobank data were managed using Laboratory Assistant Suite49. Animal procedures were approved by the Italian Ministry of Health (authorization letter 806 / 2016-PR).

[0184] Two-way ANOVA was used to calculate the statistical significance of tumor volume changes during treatment. For endpoint comparisons, statistical analysis was performed by two-tailed unpaired Welch t test. Statistical analysis in survival experiments was performed by log-rank (Mantel-Cox) test. For all tests, the statistical significance level was set to p<0.05. GraphPad Prism (v9.0) statistical software package was used to generate graphs and perform statistical analysis.

[0185] Figure 8 a shows the changes in tumor volume over time. Figure 8 b shows the change in tumor volume at the end point. Figure 8 c shows the survival of SNU-81 transplanted mice after the end of treatment. As can be seen from the figure, the effect of the combination therapy on the end of treatment tumor volume and tumor growth inhibition over time was more significant than that of irinotecan alone (Welch t test, p < 0.05) ( Figure 8 In SNU-81, although the combination therapy was more similar to irinotecan alone, the recovery of tumor growth after drug withdrawal was delayed in mice treated with the combination compared with mice treated with irinotecan alone (log-rank Mantel-Cox test, endpoint 750 mm 3 ), which indicates an adaptive disadvantage ( Figure 8 c).

[0186] Example 8

[0187] Effects of CHEK1i and TOPi on DNA double-strand breaks, cell apoptosis and proliferation in tumors

[0188] After 4-week follow-up, the tumors were treated with vehicle (until tumors reached 1500 mm 3Morphometric quantification of Ki67, active caspase-3 (active cas-3) and phosphorylated-H2AX immunoreactivity was performed in LS-1034 xenografts of mice treated with either the indicated compound (average volume of 200 μg / mL) or the indicated compound (after 72 hours). Tumors were transplanted (n=1-3 for each treatment group) and histological quality inspection and immunohistochemical analysis were performed with the following antibodies: mouse anti-Ki-67 (MIB-1) (Dako#GA626), rabbit anti-cleaved caspase-3 (Asp175) (Cell Signaling#9661) and rabbit anti-phosphorylated histone H2AX (Ser139) (20E3) (Cell Signaling#9718). After incubation with secondary antibodies, immunoreactivity was visualized by DAB chromogen (Dako). Images were captured using a Leica DM LB microscope with Leica LAS EZ software. Morphometric quantification was performed using spectral image segmentation with ImageJ software. Software output was manually verified by visual inspection of digital images. Each point represents the value measured in one light field (40× for Ki67 and phospho-H2AX; 20× for active caspase-3), with 2-10 light fields (Ki67 and phospho-H2AX) and 3-5 light fields (active caspase-3) per tumor, depending on the range of section area (n=12-30 for Ki67 and phospho-H2AX; n=10-15 for active caspase-3). Graphs show mean ± SD. Mean + / - SD. Statistical analysis was performed by two-tailed unpaired Welch t-test.

[0189] The results are shown in Fig. 9 In this study, the combination resulted in increased DNA double-strand breaks (phospho-H2AX-positive cells), more apoptotic cells (active caspase-3-positive cells), and fewer proliferating cells (reduced Ki67-positive cells) in tumors in vivo.

[0190] Example 9

[0191] IC of siCHEK1 to TOP1i 50 Impact

[0192] SW837 and SNU-81 cells (8,000 and 16,000 cells per well, respectively) were reverse transfected with siRNAs from a non-targeting pool (siNT; Dharmacon, D-001810-10-05) as a negative control, a CHEK1 pool (Dharmacon, L-003255-00-0005), or a CHEK2 pool (Dharmacon, L-003256-00-0005) using lipofectamine RNAiMax (Thermofisher). After 30 hours, SN-38 or DMSO was added at a dose range of 0.001-9 μM, and viability was measured with CTG after 72 hours. Signals were normalized to siNT+DMSO controls. Mean ± SD of three independent replicates.

[0193] The results are shown in Table 4 and Fig.10 siCHEK1 changes the IC of TOP1i 50 , indicating that loss of CHEK1 sensitizes cells to TOP1i. These results are consistent with inhibition of CHEK1 leading to increased sensitivity to TOP1i and suggest that combination therapy of CHEK1i and TOP1i could be used to reduce the dose of TOP1i administered to patients in the clinic, potentially reducing clinical toxicities associated with TOP1 inhibition.

[0194] Table 4

[0195]

[0196] Example 10

[0197] Other CHEK1 and topoisomerase inhibitor SN-38 combinations in colon cancer cell lines method:

[0198] Screening was performed in three colon cancer cell lines (CL-11, SNU-81, and SW837) using a 7×7 matrix approach, generating data from 49 wells per cell line / drug combination. For each combination, a CHEK1 inhibitor was combined with SN-38 over a discrete 1,000-fold (7-point) dose range. Viability was measured using CellTiter-Glo reagent 72 hours after drug treatment. Viability measurements for single agents and combinations were fitted by cell line, and multiple parameters were derived, including single agent values ​​and a range of synergy scores.

[0199] For all 49 concentration combinations measured, Bliss excess was calculated by comparing the observed combined response of cells to the response predicted by the Bliss-independent model based on the activity of the monotherapies. The 'Bliss window' is reported as the highest average Bliss excess value measured in 25 possible 3x3 sub-matrices or 'windows' within the 7x7 dose matrix.

[0200] In addition, the HSA (highest single agent) excess measured for all 49 concentration combinations was calculated by comparing the observed combined response of cells to the highest single agent response in either Drug A or Drug B, whichever was highest. The “HSA window” is reported as the highest mean HSA excess value measured in 25 possible 3×3 sub-matrices or “windows” within the 7×7 dose matrix.

[0201] result:

[0202] The screen included SN-38 (a topoisomerase I inhibitor) in combination with each of the following CHEK1 inhibitors: MK-8776, prasetin, rabusertib, SAR-020106, SRA737. All three cell lines were MSS and KRAS / TP53 double mutant. The results showed that the synergy of SN-38 in combination with any CHEK1 inhibitor was high, as seen by the high scores in the Bliss window and the HSA window ( Fig.11 ).

[0203] discuss

[0204] The inventors interpret the results to show that the combination of TOP1 inhibitor plus CHEK1 inhibition is synergistic in MSS or KRAS-TP53 double mutant colon cancer cells, leading to inhibition of apoptosis and tumor xenograft growth.

[0205] Camptothecin is an analog of irinotecan, a standard of care chemotherapeutic agent used to treat colon cancer, and CHEK1 inhibitors (including AZD7762) have been shown to enhance the response of DNA damaging compounds by abolishing DNA damage-induced cell cycle arrest. Notably, the inventors observed that the combination produced high synergy rates in MSS colon cancer cell lines (62.1% and 53.3% for both screening configurations) and showed significantly higher potency and efficacy in MSS cell lines than in MSI cell lines (two-sided Welch t-test, p<0.001, Figure 1 a). In addition, KRAS mutant colon showed high synergy to the combination (46% and 48%), and the inventors found that KRAS-TP53 double mutant cell lines had significantly stronger combination response than KRAS single mutant cell lines (two-sided Welch t test, p<0.0001, Figure 1 b) Thus, the inventors identified two potential molecular backgrounds, MSS and KRAS-TP53 double mutant colon, which significantly benefited from the combination of CHEKi and TOP1i.

[0206] To confirm the observed synergy and investigate whether the synergy depends on the inhibition of CHEK1, CHEK2 or both, the inventors combined camptothecin with six CHEK inhibitors with different specificities. When tested in four cell lines, the CHEK1 selective inhibitors SAR-020106 and rabusertib combined with camptothecin resulted in efficacy (median ΔIC 50 : 8.5-10.5-fold change) and efficacy (median ΔE max :0.22-0.24), while the CHEK2 selective inhibitor CCT241533 did not ( Figure 3 ). In addition, combining SN-38, the active metabolite of the TOP1 inhibitor irinotecan, with siRNA targeting CHEK1 but not CHEK2 resulted in a synergistic reduction in activity ( Figures 3 to 5 ). Addition of siCHEK1 but not siCHEK2 resulted in an IC 50 At least 7-fold change [SNU-81: 7.2-fold (IC 50 siNT: 611.1nM; siCHEK1: 84.4nM; siCHEK2: 714.7nM); SW837: 120-fold (IC 50 siNT: 84.4 nM; siCHEK1: 0.69 nM; siCHEK2: 66.6 nM)], suggesting that modulation of CHEK1 can be used to reduce the dose of TOP1 inhibitors. The results indicate that the combined effect of TOP1i+CHEKi is mainly mediated by inhibition of CHEK1.

[0207] The inventors next evaluated the combination using a colony formation assay. Combining low concentrations of SN-38 with rabusertib (CHEK1) resulted in less colony formation and increased cell death compared to either drug alone or when SN-38 was combined with CCT241533 (CHEK2) ( Figure 5 and 6 ). For many colon cell lines, particularly those with weak to moderate responses to SN-38 alone, the cell death effects of SN-38 + rabusertib exceeded the additive response, consistent with CHEK1 inhibition potentiating the effects of TOP1 inhibition. The combination effects in colon cell lines ranged from less than additive to robust enhancement, with all MSS cell lines and most KRAS mutant cell lines showing at least an additive response. We further found that the combination was associated with caspase 3 / 7 activation as well as PARP cleavage, both markers of apoptosis ( Figure 7 ).

[0208] To investigate the effect of the combination of TOP1i and CHEK1i on tumor growth in vivo, the inventors transplanted three colon cancer cell lines (LS-1034, SW837, SNU-81) into NOD / scid mice and treated them with irinotecan (TOP1), rabusertib (CHEK1), or a combination of the two drugs. In LS-1034 and SW837, the combination of TOP1i and CHEK1i showed more cell death in vitro than SNU-81 ( Figure 6 ), the effects of the combination therapy on end-of-treatment tumor volume and tumor growth inhibition over time were more pronounced than those of irinotecan alone (Welch t test, p<0.05); in SNU-81, the effects of the combination therapy were more similar to those exerted by irinotecan alone ( Figure 8 a and b). However, the recovery of SNU-81 tumor growth after drug withdrawal was delayed in mice treated with the combination compared with mice treated with irinotecan alone (log-rank Mantel-Cox test, endpoint 750 mm 3 ), which indicates an adaptive disadvantage ( Figure 8 c). In addition, the combination treatment resulted in more DNA double-strand breaks (phospho-H2AX-positive cells), less proliferating, and more apoptotic tumor cells than observed in irinotecan-treated LS-1034 tumors 72 hours after the start of treatment ( Fig. 9 ).

[0209] Overall, the inventors believe that these data validate the combination of TOPi and CHEK1i as an effective combination in MSS and KRAS-TP53 double-mutant colon cancer cells, driving apoptosis and enhancing response compared to irinotecan alone.

[0210] As a proof of concept, the present invention validates the combination of irinotecan and CHEK1i in vitro and in vivo. Although the combination of CHEK1i and DDA is associated with TP53 and KRAS, to our knowledge, this is the first report that CHEK1i combined with chemotherapy has significant activity in MSS and KRAS-TP53 double mutant colon. Clinical trials combining CHEKi with chemotherapy have shown variable anti-tumor activity, especially for unselected patients, and are associated with toxicity. Since irinotecan is approved for the treatment of colon cancer, and rabusertib is a CHEK1 selective drug with an acceptable safety profile in a phase 1 clinical trial, these data indicate that this combination provides an effective treatment option for patients with MSS or KRAS-TP53 double mutant colon cancer with appropriate consideration of potential toxicity. These represent a population with currently unmet clinical needs, and the synergistic rate observed by the inventor exceeds the synergistic rate of the combination previously used in clinical trials or currently ongoing clinical trials. For example, non-selective CHEK inhibitors have been clinically tested in combination with chemotherapeutic agents (particularly gemcitabine) in unselected patient populations and have been largely unsuccessful due to lack of efficacy or toxicity, or both. The inventors' observations indicate that in patients with MSS or KRAS-TP53 mutant colon cancer, CHEK1 inhibition in combination with TOP1i may be particularly responsive.

[0211] References

[0212] Many publications are cited above to more fully describe and disclose the present invention and the current state of the art to which the present invention belongs. The complete citations of these references are provided below. The full text of each of these references is incorporated herein.

[0213] Berge et al., J Pharm Sci, 1977 66(1) p 1

[0214] Bliss,Annals of Applied Biology,1939,26(3),585-615

[0215] ClinicalTrials.gov Identifier:NCT01341457

[0216] EP3411036

[0217] Kawakami et al., Curr. Treat. Options Oncol., 2015 Jul;16(7):30 (PMID:26031544)

[0218] Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins

[0219] Scagliotti et al. Invest New Drugs, 2016, June 27, 34(5): 625-635 (PMID: 27350064)

[0220] Weiss et al Invest New Drugs 2013 31(1):136-44(PMID:22492020)

[0221] van Ark-Otte et al., Br J Cancer, 1998 Jun;77(12):2171-2176

[0222] https: / / www.fda.gov / medical-devices / in-vitro-diagnostics / list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

[0223] https: / / www.medicines.org.uk / emc / product / 481 / smpc#gref

[0224] https: / / reference.medscape.com / drug / camptosar-irinotecan-342252

[0225] For standard molecular biology techniques, see Sambrook, J., Russel, DW Molecular Cloning, A Laboratory Manual. 3rd ed. 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

[0226] Priority Clause

[0227] 1. A combination of a CHEK1 inhibitor and a TOP1 inhibitor for use in a method of treating colorectal cancer in a patient, wherein the TOP1 inhibitor is camptothecin.

[0228] 2. The combination for use according to clause 1, wherein the colorectal cancer is KRAS-TP53 double mutant colorectal cancer.

[0229] 3. The combination for use according to clause 1, wherein the colorectal cancer is microsatellite stable.

[0230] 4. The combination for use according to clause 1, wherein the colorectal cancer is a KRAS-TP53 double mutant and microsatellite stable colorectal cancer.

[0231] 5. The combination for use according to clause 4, wherein the camptothecin is selected from irinotecan, SN-38, topotecan and camptothecin.

[0232] 6. A combination for use according to clause 4, wherein the camptothecin is irinotecan.

[0233] 7. A combination for use according to any one of the preceding clauses, wherein the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prasetin, MK-8776, CCT245737, CHIR-124, PF477736, VX-803, GDC-0575, ESP-01 and BEBT-260.

[0234] 8. The combination for use according to clause 7, wherein the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prasetin and MK-8776.

[0235] 9. The combination for use according to clause 8, wherein the CHEK1 inhibitor is rabusertib.

[0236] 10. The combination for use according to any one of the preceding clauses, wherein the CHEK1 inhibitor and the TOP1 inhibitor are administered separately.

Claims

1. A combination of a CHEK1 inhibitor and a TOP1 inhibitor for use in a method of treating colorectal cancer in a patient, wherein the TOP1 inhibitor is a camptothecin derivative.

2. A CHEK1 inhibitor for use in a method of treating colorectal cancer in a patient, and wherein the CHEK1 inhibitor is administered to the patient in combination with a TOP1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

3. A TOP1 inhibitor for use in a method of treating colorectal cancer in a patient, wherein the TOP1 inhibitor is administered to the patient in combination with a CHEK1 inhibitor, wherein the TOP1 inhibitor is a camptothecin derivative.

4. The combination for use according to claim 1, the CHEK1 inhibitor for use according to claim 2 or the TOP1 inhibitor for use according to claim 3, wherein the colorectal cancer is KRAS-TP53 double mutant colorectal cancer.

5. The combination for use according to claim 1, the CHEK1 inhibitor for use according to claim 2 or the TOP1 inhibitor for use according to claim 3, wherein the colorectal cancer is microsatellite stable.

6. The combination for use according to claim 1, the CHEK1 inhibitor for use according to claim 2 or the TOP1 inhibitor for use according to claim 3, wherein the colorectal cancer is a KRAS-TP53 double mutant and microsatellite stable colorectal cancer.

7. The combination for use according to any one of the preceding claims, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the camptothecin derivative is selected from irinotecan, SN-38, topotecan and camptothecin.

8. The combination for use according to claim 7, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the camptothecin derivative is irinotecan.

9. The combination for use according to claim 7, the CHEK1 inhibitor or the TOP1 inhibitor, wherein the camptothecin derivative is camptothecin.

10. The combination for use according to claim 7, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the camptothecin derivative is SN-38.

11. A combination for use according to any one of the preceding claims, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prasetib, MK-8776, CCT245737, CHIR-124, PF477736, VX-803, GDC-0575, ESP-01 and BEBT-260.

12. The combination for use according to claim 11, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the CHEK1 inhibitor is selected from rabusertib, SAR-020106, AZD7762, prasetib and MK-8776.

13. The combination for use according to claim 11, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the CHEK1 inhibitor is rabusertib.

14. A combination for use according to any one of the preceding claims, a CHEK1 inhibitor or a TOP1 inhibitor, wherein the CHEK1 inhibitor and the TOP1 inhibitor are administered separately.